We considered those breast cancers with HER2 copy number “gain” but not “high gain” (amplification) to be most likely representative of ISH-equivocal cancers with increased HER2 (4-6 copies per tumor cell), but not HER2 amplification. This evidence concerns the gene ERBB2 and neoplasm.